What do GLP‐1s have to do with psychology?
The Brown University Child and Adolescent Behavior Letter · 2026-08 · 42 (8) · 8-8
DOI: 10.1002/cbl.30969 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Child and Adolescent Behavior Letter, online erschienen am 24.07.2026. Verfasst von David P. Lichtenstein. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
A physician friend who works with diabetes was prescribing GLP‐1 medications (glucagon‐like peptide agonists; brand names include Ozempic and Zepbound) targeted at diabetes and weight loss. These medicines reduce appetite in part by mimicking our satiety system — essentially, helping the body recognize earlier when it has eaten enough. Weight loss was happening for many of my friend's patients (as well as improving blood sugar and blood pressure). But one patient also noted offhand that he had lost his appetite for smoking cigarettes. Turned out he was not alone.
Zitieren
APA
Lichtenstein, D. P. (2026). What do GLP‐1s have to do with psychology?. The Brown University Child and Adolescent Behavior Letter, 42(8), 8-8. https://doi.org/10.1002/cbl.30969
Vancouver
Lichtenstein DP. What do GLP‐1s have to do with psychology?. The Brown University Child and Adolescent Behavior Letter. 2026;42(8):8-8. doi:10.1002/cbl.30969
BibTeX
@article{Lichtenstein2026,
author = {Lichtenstein, David P.},
title = {What do GLP‐1s have to do with psychology?},
journal = {The Brown University Child and Adolescent Behavior Letter},
year = {2026},
volume = {42},
number = {8},
pages = {8--8},
doi = {10.1002/cbl.30969}
}
EUVIMED